Syndax Pharmaceuticals Inc (SNDX)

May 10, 2025

Crestline Management LP Increases Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

May 10, 2025

May 10, 2025

Guggenheim Reiterates "Buy" Rating for Syndax Pharmaceuticals (NASDAQ:SNDX) - MarketBeat

May 10, 2025

May 10, 2025

What is B. Riley's Forecast for SNDX Q2 Earnings? - MarketBeat

May 10, 2025

May 10, 2025

Bayesian Capital Management LP Makes New Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

May 10, 2025

May 10, 2025

Marshall Wace LLP Sells 977,280 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

May 10, 2025

May 10, 2025

Algert Global LLC Buys 310,634 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

May 10, 2025

May 09, 2025

Wall Street Analysts See a 219.98% Upside in Syndax (SNDX): Can the Stock Really Move This High? - Yahoo Finance

May 09, 2025

May 09, 2025

Avidity Partners Management LP Cuts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) - MarketBeat

May 09, 2025

May 08, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $17.00 - MarketBeat

May 08, 2025

May 08, 2025

Syndax Pharmaceuticals (NASDAQ:SNDX) Releases Earnings Results, Beats Estimates By $0.06 EPS - MarketBeat

May 08, 2025

May 08, 2025

Syndax Announces Participation in May Investor Conferences - The Manila Times

May 08, 2025

May 08, 2025

Analysts Are Upgrading Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) After Its Latest Results - simplywall.st

May 08, 2025

May 07, 2025

SNDX: Syndax Reveals Significant Phase 2 Trial Results for Revumenib | SNDX Stock News - GuruFocus

May 07, 2025

May 07, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $36.20 Average Target Price from Analysts - MarketBeat

May 07, 2025

May 07, 2025

Syndax Announces Publication of Pivotal Revumenib Data in - GlobeNewswire

May 07, 2025

May 07, 2025

Syndax Announces Publication of Pivotal Revumenib Data in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia in the Journal Blood - Yahoo Finance

May 07, 2025

May 07, 2025

Syndax signals $4B total market opportunity with Revuforj expansion into frontline settings - MSN

May 07, 2025

May 07, 2025

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2025 Earnings Call Transcript - Insider Monkey

May 07, 2025

May 06, 2025

Syndax Pharmaceuticals’ Optimistic Q1 2025 Earnings Call - TipRanks

May 06, 2025

May 06, 2025

SNDX: Scotiabank Raises Price Target on Syndax Pharmaceuticals | SNDX Stock News - GuruFocus

May 06, 2025

May 06, 2025

Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenhei - GuruFocus

May 06, 2025

May 06, 2025

Syndax Pharmaceuticals (SNDX) Buy Rating Reiterated by Guggenheim | SNDX Stock News - GuruFocus

May 06, 2025

May 06, 2025

Scotiabank raises Syndax stock target to $17 on strong sales By Investing.com - Investing.com Canada

May 06, 2025

May 06, 2025

Syndax (SNDX) Price Target Increased by BofA Following Promising Updates | SNDX Stock News - GuruFocus

May 06, 2025

May 06, 2025

BofA raises Syndax stock price target to $26 on strong Q1 update - Investing.com Canada

May 06, 2025

May 06, 2025

Syndax Pharmaceuticals Q1 Loss Widens - marketscreener.com

May 06, 2025

May 06, 2025

Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo

May 06, 2025

May 06, 2025

Syndax Pharmaceuticals Inc (SNDX) Q1 2025 Earnings Call Highligh - GuruFocus

May 06, 2025

May 06, 2025

SNDX Reports Strong Revenue and Cash Position, Focuses on Growth - GuruFocus

May 06, 2025

May 06, 2025

Syndax Pharmaceuticals Reports Strong Q1 2025 Results - TipRanks

May 06, 2025

May 06, 2025

Earnings call transcript: Syndax Pharmaceuticals beats Q1 2025 EPS estimates - Investing.com Canada

May 06, 2025

May 06, 2025

Decoding Syndax Pharmaceuticals Inc (SNDX): A Strategic SWOT Ins - GuruFocus

May 06, 2025

May 05, 2025

Syndax Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:SNDX) - Seeking Alpha

May 05, 2025

May 05, 2025

Syndax: Q1 Earnings Snapshot - MySA

May 05, 2025

May 05, 2025

Syndax Pharmaceuticals earnings beat by $0.26, revenue topped estimates - Investing.com Canada

May 05, 2025

May 05, 2025

Syndax Pharmaceuticals Q1 2025 Earnings: EPS Loss of $0.98 Beats Estimates, Revenue Surges to $20 Million - GuruFocus

May 05, 2025

May 05, 2025

Syndax Q1 2025 slides: Revuforj revenue hits $20M, cash position remains strong - Investing.com India

May 05, 2025

May 05, 2025

Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 05, 2025

May 05, 2025

Syndax Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 05, 2025

May 05, 2025

Syndax Q1 2025 slides: Revuforj revenue hits $20M, cash position remains strong By Investing.com - Investing.com South Africa

May 05, 2025

May 05, 2025

SNDX Reports Impressive Q1 Revenue, Exceeds Market Expectations | SNDX Stock News - GuruFocus

May 05, 2025

May 05, 2025

Earnings Flash (SNDX) Syndax Pharmaceuticals Posts Q1 Revenue $20M, vs. FactSet Est of $15.6M - marketscreener.com

May 05, 2025

May 05, 2025

Syndax Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire

May 05, 2025

May 05, 2025

Syndax Pharmaceuticals (SNDX) Projected to Post Earnings on Tuesday - MarketBeat

May 05, 2025